1
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 26, 1997
COULTER PHARMACEUTICAL, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-21905 94-3219075
(Commission File No.) (IRS Employer Identifications No.)
550 CALIFORNIA AVENUE, SUITE 200
PALO ALTO, CA 94306-1440
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (415) 842-7300
2
Item 5. Other Events.
Coulter Pharmaceutical, Inc. (the "Company") and Lonza Biologies PLC
("Lonza") entered into the Third Amendment to the Manufacturing Agreement, dated
September 26, 1997 (the "Third Amendment"), and the Fourth Amendment to the
Manufacturing Agreement, dated September 17, 1997 (the "Fourth Amendment"). The
Third Amendment and the Fourth Amendment are part of a series of amendments to
the original Manufacturing Agreement between the Company and Lonza, dated August
20, 1996. The Company had contracted with Lonza as a third-party manufacturer to
produce unlabeled B-1 Antibody for use in clinical trials of the Company's most
advanced product candidate Bexxar (formerly known as the "B-1 Therapopy").
1.
3
Item 7. Exhibits.
10.13* Third Amendment to Manufacturing Agreement, dated
September 26, 1997, by and between Lonza Biologies
PLC and the Registrant.
10.14* Fourth Amendment to Manufacturing Agreement, dated
September 17, 1997, by and between Lonza Biologies
PLC and the Registrant.
- --------------
* Portions omitted pursuant to a request of confidentiality filed separately
with the Commission.
4.
4
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
COULTER PHARMACEUTICAL, INC.
Dated: September 26, 1997
By: /s/ WILLIAM G. HARRIS
----------------------------------
William G. Harris
Vice President and
Chief Financial Officer
5.
5
INDEX TO EXHIBITS
-----------------
10.13* Third Amendment to Manufacturing Agreement, dated
September 26, 1997, by and between Lonza Biologies
PLC and the Registrant.
10.14* Fourth Amendment to Manufacturing Agreement, dated
September 17, 1997, by and between Lonza Biologies
PLC and the Registrant.
- --------------
* Portions omitted pursuant to a request of confidentiality filed separately
with the Commission.